What are Arixtra's inactive ingredients?
Arixtra (fondaparinux sodium) contains sodium citrate, hydrochloric acid, sodium hydroxide, and water for injection as inactive ingredients [1]. These components are used to formulate the drug and ensure its stability and delivery.
Why are inactive ingredients important in medications like Arixtra?
Inactive ingredients, also known as excipients, play a crucial role in drug formulation and administration. They can affect how a drug is absorbed, its stability, and how it is administered. For Arixtra, these inactive ingredients help create a sterile solution suitable for injection [1].
What is Arixtra used for?
Arixtra is a synthetic, selective factor Xa inhibitor. It is used to prevent blood clots in adults, including those undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery, or abdominal surgery. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults [1].
How does Arixtra work?
Arixtra works by selectively inhibiting activated factor X (factor Xa). Factor Xa is a key enzyme in the blood coagulation cascade, and its inhibition prevents the formation of thrombin, which is essential for clot formation [1]. This mechanism helps to reduce the risk of blood clots.
Where can I find detailed information on Arixtra's formulation?
Detailed information on Arixtra's inactive ingredients and formulation can be found in its prescribing information, often available through resources like DailyMed [1].
What is the drug's patent status?
Information on the patent status of drugs like Arixtra is often tracked by specialized databases. DrugPatentWatch.com provides data on pharmaceutical patents, which can indicate when market exclusivity for a drug might end [2].
Sources:
1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e01b934-6b93-410b-9595-54d5c3758b95
2. https://drugpatentwatch.com/